|
gptkbp:instance_of
|
gptkb:biotechnology
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:acquisition
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:acquisition_year
|
gptkb:2019
|
|
gptkbp:advocacy
|
support organizations
|
|
gptkbp:biomarker_development
|
targeted therapies
|
|
gptkbp:biotechnology_sector
|
innovative therapies
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:capital
|
gptkb:public_company
|
|
gptkbp:ceo
|
gptkb:Josh_Bilenker
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
targeted therapies
precision medicine
positive outcomes
overall survival
published data
adaptive trials
|
|
gptkbp:collaboration
|
academic institutions
|
|
gptkbp:collaborations
|
pharmaceutical companies
biotech companies
biopharma partners
|
|
gptkbp:drug_approval_process
|
regulatory agencies
|
|
gptkbp:drug_commercialization
|
market launch
|
|
gptkbp:drug_discovery
|
innovative technologies
|
|
gptkbp:drug_efficacy
|
clinical trials
|
|
gptkbp:drug_mechanism
|
inhibitor
|
|
gptkbp:drug_safety
|
clinical assessments
|
|
gptkbp:eligibility
|
clinical studies
|
|
gptkbp:financial_performance
|
revenue growth
|
|
gptkbp:focus
|
targeted cancer therapies
|
|
gptkbp:focuses_on
|
targeted cancer therapies
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:Josh_Bilenker
|
|
gptkbp:funding
|
grants and investments
|
|
gptkbp:has_advisory_board
|
experts in oncology
|
|
gptkbp:headquarters
|
gptkb:Boulder,_Colorado
|
|
gptkbp:healthcare
|
gptkb:cancer_treatment
gptkb:2018
oral administration
accelerated pathway
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Loxo Oncology
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:initiatives
|
cancer genomics
|
|
gptkbp:instruction_set
|
multiple drug candidates
|
|
gptkbp:investment
|
venture capital firms
public disclosures
R& D
|
|
gptkbp:investment_focus
|
rare cancers
|
|
gptkbp:ipo
|
gptkb:2018
|
|
gptkbp:key_people
|
gptkb:Jennifer_A._Doudna
gptkb:Michael_A._O'_Connor
gptkb:David_Hyman
gptkb:Megan_H._Mc_Carthy
Robert A. Darnell
|
|
gptkbp:leadership
|
Josh Bilenker, CEO
|
|
gptkbp:market_position
|
oncology sector
|
|
gptkbp:marketing_strategy
|
global expansion
partnerships and collaborations
|
|
gptkbp:notable_products
|
gptkb:LOXO-292
gptkb:Vitrakvi
|
|
gptkbp:parent_company
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:partnership
|
gptkb:Eli_Lilly_and_Company
collaborative development
|
|
gptkbp:partnerships
|
hospitals and clinics
|
|
gptkbp:patient_population
|
cancer patients
|
|
gptkbp:patient-centric_approach
|
treatment options
|
|
gptkbp:publications
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
FDA guidelines
|
|
gptkbp:related_products
|
gptkb:Retevmo
gptkb:LOXO-292
gptkb:Vitrakvi
|
|
gptkbp:research
|
cancer biology
|
|
gptkbp:research_areas
|
oncology
molecularly targeted therapy
|
|
gptkbp:research_focus
|
genetic mutations
molecular targets
|
|
gptkbp:side_effect
|
cancer care
|
|
gptkbp:social_responsibility
|
patient advocacy
|
|
gptkbp:stock_exchange
|
NASDAQ: LOXO
|
|
gptkbp:stock_symbol
|
gptkb:LOXO
|
|
gptkbp:therapeutic_advancements
|
cancer treatment options
|
|
gptkbp:therapeutic_pipeline
|
multiple indications
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:treatment
|
improved survival rates
|
|
gptkbp:website
|
www.loxooncology.com
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly
gptkb:Blueprint_Medicines
|
|
gptkbp:bfsLayer
|
4
|